EGFR and adenocarcinoma: Likewise, despite statistical adjustments for the number of patients with adenocarcinoma, the possibility of a sex-based imbalance in actionable driver mutations (e.g. EGFR, ALK) within our cohort and its impact on key endpoints cannot be excluded.